Selexipag: An Oral and Selective IP Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension
mediaposted on 17.12.2015, 09:50 by Tetsuo Asaki, Keiichi Kuwano, Keith Morrison, John Gatfield, Taisuke Hamamoto, Martine Clozel
Prostacyclin controls cardiovascular function via activation of the prostacyclin receptor. Decreased prostacyclin production occurs in several cardiovascular diseases. However, the clinical use of prostacyclin and its analogues is complicated by their chemical and metabolic instability. A medicinal chemistry program searched for novel nonprostanoid prostacyclin receptor agonists not subject to these limitations. A compound with a diphenylpyrazine structural core was synthesized. Metabolic stability and agonist potency were optimized through modification of the linear side chain. Compound 12b (MRE-269, ACT-333679) was identified as a potent and highly selective prostacyclin receptor agonist. Replacement of the terminal carboxyl group with an N-acylsulfonamide group yielded parent compound 26a (selexipag, NS-304, ACT-293987), which is orally active and provides sustained plasma exposure of 12b. Compound 26a was developed for the treatment of pulmonary arterial hypertension and shown to reduce the risk of the composite morbidity/mortality end point in a phase 3 event-driven clinical trial.
Read the peer-reviewed publication
Compound 12 bside chainparent compound 26MREnovel nonprostanoid prostacyclin receptor agonistsphase 3agonist potencyDecreased prostacyclin productionMetabolic stabilityHypertensionProstacyclin controlsNSprostacyclin receptor agonistSelective IP Prostacyclin Receptor Agonistprostacyclin receptorchemistry programplasma exposureCompound 2612 bterminal carboxyl group